OUTCOME OF AZACITIDINE TREATMENT AND INCIDENCE OF FEBRILE EVENTS IN "REAL WORLD" PATIENTS WITH MDS OR LOW-BLAST COUNT AML

被引：0

作者：

Voso, M. T. ^{[1
]}

Niscola, P. ^{[2
]}

Piciocchi, A. ^{[3
]}

Fianchi, L. ^{[4
]}

Maurillo, L. ^{[1
]}

Musto, P. ^{[5
]}

Pagano, L. ^{[4
]}

Mansueto, G. ^{[5
]}

Criscuolo, M. ^{[4
]}

Aloe-Spiriti, M. A. ^{[6
]}

Buccisano, F. ^{[1
]}

Venditti, A. ^{[1
]}

Tendas, A. ^{[2
]}

Piccioni, A. L. ^{[7
]}

Zini, G. ^{[4
]}

Latagliata, R. ^{[8
]}

Filardi, N. ^{[9
]}

Fragasso, R. ^{[10
]}

Fenu, S. ^{[11
]}

Breccia, M. ^{[8
]}

机构：

[1] Univ Roma Tor Vergata, Hematol Biomed & Prevent, Rome, Italy

[2] S Eugenio Hosp, Hematol, Rome, Italy

[3] Univ Roma La Sapienza, Stat Sci, I-00185 Rome, Italy

[4] Univ Cattolica Sacro Cuore, Hematol, Rome, Italy

[5] IRCCS CROB MDS Registry Basilicata, Hematol, Rionero In Vulture, Pz, Italy

[6] S Andrea Hosp, Hematol, Rome, Italy

[7] S Pertini Hosp, Hematol, Rome, Italy

[8] Univ Roma La Sapienza, Hematol, I-00185 Rome, Italy

[9] S Carlo Hosp MDS Registry Basilicata, Hematol, Potenza, Italy

[10] Madonna delle Grazie Hosp MDS Registry Basilicata, Hematol, Matera, Italy

[11] S Giovanni Hosp, Hematol, Rome, Italy

来源：

LEUKEMIA RESEARCH | 2015年 / 39卷

关键词：

D O I：

10.1016/S0145-2126(15)30199-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

198

引用

页码：S99 / S99

页数：1

共 44 条

[31] Phase 3 study of first line pevonedistat (PEV) plus azacitidine (AZA) versus single-agent AZA in patients with higher-risk myelodysplastic syndromes (HR MDS), chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (AML).
Sekeres, Mikkael A.
Fram, Robert J.
Hua, Zhaowei
Ades, Lionel
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[32] Acute Myeloid Leukemia (AML) Treated with Azacitidine: Survival Outcomes for Patients Who Complete More Than Six Cycles Are Similar to High-Risk Myelodysplastic Syndrome/Low Blast Count AML
Fulcher, Jill
Alshammasi, Zahra Abdrabalamir
Cantor, Nathan
Bredeson, Christopher
Christou, Grace
Maze, Dawn
Sabloff, Mitchell
Fulcher, Jill
BLOOD, 2019, 134
[33] Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group
Papageorgiou, Sotirios
Papadopoulos, Vasileios
Menelaos, Papoutselis
Bouhla, Anthi
Symeonidis, Argiris
Galanopoulos, Athanasios
Viniou, Nora-Athina
Hatzimichael, Eleftheria
Gogos, Dimitrios
Zikos, Panagiotis
Vassilakopoulos, Theodoros P.
Kourakli, Alexandra
Giannoulia, Panagiota
Vrachiolias, George
Megalakaki, Aikaterini
Diamantopoulos, Panagiotis T.
Poulakidas, Elias
Vardi, Anna
Anagnostopoulos, Achilles
Mparmparousi, Despoina
Papaioannou, Maria
Mpouronikou, Eleni
Papadaki, Helen A.
Dimou, Maria
Panayiotidis, Panayiotis
Pappa, Vassiliki
Kotsianidis, Ioannis
BLOOD, 2019, 134
[34] Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States
Shenolikar, Rahul
Durden, Emily
Meyer, Nicole
Lenhart, Gregory
Moore, Kathleen
GYNECOLOGIC ONCOLOGY, 2018, 151 (02) : 190 - 195
[35] Association of Changes in Transfusion Status with Changes in Health-Related Quality of Life of Real-World Patients with MDS Across Six Months of Treatment with Azacitidine
Pashos, Chris L.
Grinblatt, David L.
Sekeres, Mikkael A.
Komrokji, Rami S.
Narang, Mohit
Swern, Arlene S.
Street, Thomas K.
Sullivan, Kristen A.
Harding, Gale
Khan, Zeba M.
BLOOD, 2011, 118 (21) : 1205 - 1206
[36] Low incidence of adverse liver events in a real-world cohort of patients diagnosed with liver disease via a community diagnostic pathway
Smith, Alexander
Borca, Florina
Parkes, Julie
Patel, Janisha
Phan, Hang
Robins, Callum
Buchanan, Ryan
JOURNAL OF HEPATOLOGY, 2022, 77 : S909 - S909
[37] LOW INCIDENCE OF ADVERSE LIVER EVENTS IN A REAL-WORLD COHORT OF PATIENTS DIAGNOSED WITH LIVER DISEASE VIA A COMMUNITY DIAGNOSTIC PATHWAY
Smith, Alexander
Buchanan, Ryan
Borca, Florina
Phan, Hang
Patel, Janisha
Robins, Callum
Parkes, Julie
GUT, 2022, 71 : A56 - A57
[38] LOW-DOSE CYTARABINE AFTER FAILURE OF 5-AZACITIDINE AS PALLIATIVE TREATMENT FOR ELDERLY PATIENTS WITH AML OR HIGH-RISK MDS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY. A RETROSPECTIVE SINGLE CENTER ANALYSIS
Jakob, C.
Peinert, S.
Breywisch, F.
Guenther, B.
Dittberner, K.
Boger, L.
Rothmann, F.
Maschmeyer, G.
HAEMATOLOGICA, 2015, 100 : 386 - 386
[39] Real-World Experience with Selinexor -Containing Regimens in Post-Transplant AML/MDS Patients Who MRD Still Positive after First-Line Preemptive Treatment
Tong, Xiwen
Su, Shuai
Xu, Bin
Zhu, Xiaojian
Peng, Yizhou
Jie, Jin
Mao, Xia
Xiao, Min
Mei, Jay
Zhang, Donghua
BLOOD, 2023, 142
[40] What is the real-world risk of MDS/AML and other secondary primary malignancies in patients with epithelial ovarian cancer treated with niraparib maintenance treatment? Interim results from a regulatory safety study
Kommoss, Stefan
Tasca, Giulia
Boyle, Tirza Areli Calderon
Golembesky, Amanda
Schilder, Jeanne M.
Malinowska, Izabela A.
Ye, Guilan
Kuplast, Judi
Perhanidis, Jessica
Zeliku, Zoe
Alonso, Constanza Maximiano
Vorst, Maurice Van Der
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A301 - A302

← 1 2 3 4 5 →